Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitoxantrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 6/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.84 |
| ▸ | LMNA | P02545 | 4/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.84 |
| ▸ | BLM | P54132 | 4/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.84 |
| ▸ | RECQL | P46063 | 3/20 | 0.84 |
| ▸ | NSD2 | O96028 | 3/20 | 0.84 |
| ▸ | NPC1 | O15118 | 3/20 | 0.84 |
| ▸ | RAB9A | P51151 | 3/20 | 0.84 |
| ▸ | USP2 | O75604 | 2/20 | 0.84 |
| ▸ | TP53 | P04637 | 2/20 | 0.84 |
| ▸ | MTOR | P42345 | 2/20 | 0.84 |
| ▸ | EGFR | P00533 | 2/20 | 0.84 |
| ▸ | HTT | P42858 | 2/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.84 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.84 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18567079 | 0.96 | TOP2B (0.86) | MEN1KMT2ALMNAMAPK1BLM | |
| Mitoxantrone SCHEMBL29720597 | 0.92 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1BLM | |
| SCHEMBL11036806 | 0.92 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1BLM | |
| Mitoxantrone SCHEMBL29353270 | 0.92 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1BLM | |
| Mitoxantrone SCHEMBL20214110 | 0.92 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1BLM | |
| SCHEMBL11517949 | 0.92 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1BLM | |
| Mitoxantrone SCHEMBL3000 | 0.92 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1BLM | |
| SCHEMBL11041207 | 0.92 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1BLM | |
| SCHEMBL11391594 | 0.92 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1BLM | |
| SCHEMBL11038495 | 0.92 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622990-B2 | VAP polypeptide and use thereof in preparation of drug for targeted diagnosis and treatment of tumor | FUDAN UNIVERSITY (CN) | 2023-04-11 | — | — | US | claimed |
| US-20190314446-A1 | VAP POLYPEPTIDE AND USE THEREOF IN PREPARATION OF DRUG FOR TARGETED DIAGNOSIS AND TREATMENT OF TUMOR | FUDAN UNIVERSITY (CN) | 2019-10-17 | — | — | US | claimed |
| EP-3553074-A1 | VAP POLYPEPTIDE AND USE THEREOF IN PREPARATION OF DRUG FOR TARGETED DIAGNOSIS AND TREATMENT OF TUMOR | Fudan University (CN) | 2019-10-16 | — | — | EP | claimed |
| EP-2676953-B1 | HEMIFUMARATE SALT OF 1-[4-[1-(4-CYCLOHEXYL-3 -TRIFLUOROMETHYL-BENZYLOXYIMINO)-ETHYL]-2-ETHYL-BENZYL]-AZETIDINE-3-CARBOXYLIC ACID FOR USE IN THE TREATMENT OF LYMPHOCYTE MEDIATED DISEASES | NOVARTIS AG (CH) | 2017-03-22 | — | — | EP | claimed |
| EP-1633336-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2016-06-22 | — | — | EP | claimed |
| EP-2676953-A1 | Hemifumarate Salt and Medical Indications | Novartis AG (CH) | 2013-12-25 | — | — | EP | claimed |
| US-8609860-B2 | Acid-labile trigger units | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2013-12-17 | — | — | US | claimed |
| EP-2266964-B1 | Acid-labile trigger units | KTB TUMORFORSCHUNGS GMBH (DE) | 2013-01-09 | — | — | EP | claimed |
| US-20120142711-A1 | ACID-LABILE TRIGGER UNITS | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2012-06-07 | — | — | US | claimed |
| WO-2010149326-A1 | ACID-LABILE TRIGGER UNITS | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2010-12-29 | — | — | WO | claimed |
| EP-2266964-A1 | Acid-labile trigger units | KTB Tumorforschungsgesellschaft mbH (DE) | 2010-12-29 | — | — | EP | claimed |
| US-20040167134-A1 | Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent | BRUNS CHRISTIAN (DE) | 2004-08-26 | — | — | US | claimed |
| US-20240240255-A1 | BICYCLE CONJUGATES SPECIFIC FOR NECTIN-4 AND USES THEREOF | BICYCLETX LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239743-A1 | 1-(4-{1-[(E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO]-ETHYL}-2-ETHYL-BENZYL)-AZETIDINE-3-CARBOXYLIC ACID, (E)-BUT-2-ENEDIOIC ACID | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2002092091-A1 | COMBINATION COMPRISING N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2PYRIMIDINE-AMINE AND A CHEMOTHERAPEUTIC AGENT | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002066019-A2 | CANCER TREATMENT | NOVARTIS AG (CH) | 2002-08-29 | — | — | WO | disclosed |
| EP-1178831-A1 | COMBINED METHOD OF TREATMENT COMPRISING AN AROMATASE INHIBITOR AND A FURTHER BIOLOGICALLY ACTIVE COMPOUND | PHARMACIA & UPJOHN S.p.A. (IT) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000069467-A1 | COMBINED METHOD OF TREATMENT COMPRISING AN AROMATASE INHIBITOR AND A FURTHER BIOLOGICALLY ACTIVE COMPOUND | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240240255-A1 | BICYCLE CONJUGATES SPECIFIC FOR NECTIN-4 AND USES THEREOF | NECTIN4, CD274, SIGLEC7 | TOP2A 3867/4885MEN1 1072/4885KMT2A 3654/4885 |
| US-20120142711-A1 | ACID-LABILE TRIGGER UNITS | ASIC1, ABL1, CA9 | TOP2A 2370/4885MEN1 231/4885KMT2A 4093/4885 |
| US-20240239743-A1 | 1-(4-{1-[(E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO]-ETHYL}-2-ETHYL-BENZYL)-AZETIDINE-3-CARBOXYLIC ACID, (E)-BUT-2-ENEDIOIC ACID | ETV1, QDPR, SLC10A1 | TOP2A 4365/4885MEN1 1489/4885KMT2A 3465/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TOP2A 3390/4885MEN1 4055/4885KMT2A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.